Financial Statement 12/13 September 2012 – August 2013

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Oct 10, 2013 at 2:45 AM

Financial Statement 12/13

September 2012 – August 2013 Diamyd Medical AB (publ), former Diamyd Therapeutics AB Fiscal year 2012/2013 Reporting period, June 1, 2013 – August 31, 2013 · Net sales amounted to MSEK 0.1 (0) · Loss before tax amounted to MSEK -4.3 (-4.2) · Liquid assets amounted to MSEK 65.5 (22.0) as of August 31, 2013 Full year, September 1, 2012 – August 31, 2013 · Net sales amounted to MSEK 0.1 (0.5) · Loss before tax amounted to MSEK -12.6 (-16.3) Significant events during the reporting period June 1, 2013 – August 31, 2013 · Diamyd Medical’s rights issue was oversubscribed and raised approximately MSEK 21 · Diamyd Medical expanded its Scientific Advisory Board Significant events after the reporting period · Major owner increased holdings in Diamyd Medical CEO Comments After an intense period in May and June with the listing on First North, and an oversubscribed rights issue, Diamyd Medical’s focus has shifted to business development activities and the production of a new batch of the diabetes vaccine Diamyd®. Our current inventory needs to be renewed and the manufacturing process has evolved since we last made a batch for clinical use. Having sufficient inventory of fresh diabetes vaccine available is vital for our strategy of collaborating with externally funded research groups to establish additional clinical pilot studies with Diamyd®. Both in combination with other drugs to achieve a strong beta cell preserving effect, and by treating earlier in the disease process to try to prevent the onset of type 1 diabetes and other autoimmune diabetes altogether. Manufacturing of the new batch was carried out late September in the Netherlands and was completed without problems. Pharmaceutical manufacturing is subject to a strict regulatory framework called Good Manufacturing Practice (GMP), which sets high quality standards. Currently a wide range of tests are performed on the product to confirm that it meets all manufacturing specifications. We expect that the new vials with the diabetes vaccine Diamyd®will be released for use in clinical trials later this autumn. We work in parallel with several academic research groups who have ideas for new studies with the diabetes vaccine. The advantage of this approach is that we can test more hypotheses than if we were to conduct and fund all studies with the diabetes vaccine ourselves. The downside compared to company-funded studies, is that it takes more time since we are dependent upon the scientists actively working on the projects and seeking and receiving grants, at the same time as they are busy with their regular work at their respective hospitals. Two researcher-initiated studies with Diamyd®are already in progress. The study DIABGAD-1 evaluates treatment with the diabetes vaccine in combination with the anti-inflammatory drug ibuprofen and relatively high doses of vitamin D. The study was launched earlier this year and more than a third of the planned 60 patients have been enrolled. Also, since 2009 a researcher-initiated study is in progress with children at high risk of developing type 1 diabetes, with the aim to prevent the onset of the disease. Regarding business development, we are working hard to evaluate new opportunities for collaboration and deals in the field of diabetes. We have participated in several international diabetes meetings and will also be represented at the annual ISPAD Meeting (International Society for Pediatric and Adolescent Diabetes) next week, which this year will take place in Gothenburg. Also next week, at the Nordic Life Science Days in Stockholm, we will present Diamyd Medical to potential investors and partners from around the world. Stockholm, October 10, 2013 Peter Zerhouni President and CEO Diamyd Medical AB (publ) Significant events during the reporting period June 1, 2013 – August 31, 2013 Diamyd Medical’s rights issue was oversubscribed and raised approximately MSEK 21 Diamyd Medical’s share issue with preferential rights for the Company’s shareholders was oversubscribed. The Company received proceeds of MSEK 20.7 before issue expenses. Diamyd Medical expanded its Scientific Advisory Board The Company’s Scientific and Medical Advisory Board was expanded with three internationally leading experts on GABA and diabetes: Dr. Bryndis Birnir at Uppsala University, Dr. Brooke Ligon and Dr. Qinghua Wang at Toronto University. Significant events after the reporting period Major owner increased holdings in Diamyd Medical Bertil Lindkvist increased his holdings in Diamyd Medical. Bertil Lindkvist’s holdings in Diamyd Medical amounted to 2,979,286 B-shares as of September 24, 2013, which corresponds to 15.1 percent of the capital and 10.5 percent of the votes. *** To read the complete report, please see attached pdf, or visit www.diamyd.com *** For more information please contact: Peter Zerhouni, President and CEO Diamyd Medical AB (publ). Phone: +46 8 661 00 26 Diamyd Medical AB (publ), Kungsgatan 29, SE-111 56 Stockholm, Sweden Phone: +46 8 661 00 26 Fax: +46 8 661 63 68 E-mail: info@diamyd.com Reg no: 556242-3797 Note: This document has been prepared in both Swedish and English. The Swedish version shall govern in case of differences between the two documents. The document contains certain statements about the Company’s operating environment and future performance. These statements should only be regarded as reflective

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Omneky Outshines Competitors in AI Ad Scoring

Brewing a better ad with AI isn't just about the model you plug in—it's about the wizardry wrapping around it. Omneky's latest caper in the AI advertising game has snagged the spotlight, pulling a hearty 8.8 taste score on a recent TasteBench comparison. That's not a minor tweak, folks, but a whopping 1.2-point lead over the shadow-chasing curves of the next...

Veterans Transitioning to Real Estate with Scholarships

Tapping Military Skills for Civilian Gain Finding a new career after military service is a mountain of a task, but veterans now have a golden ticket into the real estate appraisal world. The Appraisal Institute's Next Mission Scholarship is throwing veterans a $1,000 life preserver to dive into a field where their military-honed skills already shine. The Power of a...

AtWork Welcomes Franchise Vet Sarah Goehring

A Strategic Move for AtWork There's a new heavyweight at AtWork, a name that's been catching attention in the franchise biz lately—Sarah Goehring. This isn't just another appointment; it's a signal flare for AtWork's ambitions. With Goehring, they're doubling down on scaling their operation and drawing in more franchise players who are ready to hit the ground running....

Coventry's Jacobs Joins European Life Settlement Execs

Neal Jacobs Steps Up in Life Settlements Coventry has added another feather to its cap with Neal Jacobs, their Senior Managing Director of Capital Markets, joining the Executive Committee of the European Life Settlement Association (ELSA). Elected at ELSA's Annual General Meeting on September 15, 2026, Jacobs brings a wealth of experience that promises to bolster the...

Think Tank Pushes for Bold Parkinson's Prevention Plan

A New Era for Parkinson's Disease Prevention The Parkinson's Foundation has rolled out its battle plan to take on Parkinson's disease from the ground up, shifting gears from managing symptoms to stopping the illness before it starts. It's about damn time, too. With the disease being the fastest-growing neurodegenerative disorder and impacting 10 million people worldwide,...

VetsinTech's AI Training Boosts Military Careers

A New Spin on Engineering Careers Sometimes it feels like every corner I turn in this market maze, there’s something about AI. It’s not just chirping in the tech world anymore; it’s banging on the doors of sectors like engineering, aerospace, and manufacturing. And now, VetsinTech is tossing its hat into the AI ring with a fresh program aimed at blending military...

Special Needs Group Partners with MAST to Enhance Accessibility

Accessible Travel Takes the Spotlight Ah, the travel biz—just when you think you’ve got it all figured out, along comes a partnership like this to shake things up. Special Needs Group, the big cheese in mobility and medical equipment rentals, is teaming up with MAST Travel Network. Together, they're rolling out initiatives to make the world a bit more accessible, even...

OmniActive's Fenavari: A New Era in Women's Health

Pioneering Women's Health with Fenavari You ever wonder why some health products get all the hype? Here's one for the book: OmniActive Health Technologies launching Fenavari, their top-tier contender in the women's health market. Now, we're not talking your run-of-the-mill supplement here. We're stepping onto a new playing field, especially with Dr. Taz Bhatia stepping...

New American Funding Expands in Carolinas with Mullinix Move

The Gathering of Mortgage Titans You don't just waltz into the mortgage world with a $2 billion track record and expect folks not to notice. Will Mullinix, a name that's become synonymous in the Carolinas with mortgage mastery, has decided to bring his influential Mullinix Mortgage Group under the banner of New American Funding. Talk about a power play. This bold strategy...

Quark Baby's Milk Warmer Debut at Vancouver & Dubai

An Unconventional Pitch for Baby Gear Quark Baby is strutting its stuff not just in Vancouver but all the way in Dubai. Yeah, we're talking about a milk warmer hitting two major expos. What's the deal with an award-winning brand from Vancouver making so much noise? From October 17-18, they're home-court at The Baby Show Vancouver, and by October 22-24, they're in Dubai at...